Germany‘s Merck has granted an exclusive license for the tumor-targeting IL-12 fusion protein currently known as M9241 to PDS Biotechnology Corporation, a US-based clinical-stage immunotherapy company with a growing pipeline of targeted immunotherapies for cancer and infectious disease.
US-based ABL, which bills itself as a pure play CDMO specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therapies, is partnering with KaliVir Immunotherapeutics on oncolytic viruses.
Up to now, the name BioNTech has popped up mostly in one breath with Pfizer, the company’s US partner in developing the mRNA-based Covid-19 vaccine marketed as Comirnaty. The German biotech, however, is increasingly broadening its horizons. On two consecutive days, Jan. 10 and Jan. 11, the company announced one major new collaboration project and gave an update on a second, both involving British companies.
